Neprilysin as a Biomarker: Challenges and Opportunities

Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care. NEP is a zinc-dependent multisubstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavo, Noemi, Prausmüller, Suriya, Bartko, Philipp E, Goliasch, Georg, Hülsmann, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2020
Materias:
Neprilysin
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479538/
https://www.ncbi.nlm.nih.gov/pubmed/32944293
http://dx.doi.org/10.15420/cfr.2019.21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479538/
https://www.ncbi.nlm.nih.gov/pubmed/32944293
http://dx.doi.org/10.15420/cfr.2019.21

Ejemplares similares